Continuing Education Activity

Coral snake envenomation represents an uncommon but potentially life-threatening toxicologic emergency, accounting for fewer than 2% of snakebites in the United States. Risk is highest among individuals engaging in outdoor activities in endemic regions and increases with delayed recognition of the characteristic red, yellow, and black banding pattern or underestimation of the minimal local tissue findings typical of elapid bites. Envenomation is caused by North American species, including Micrurus fulvius, Micrurus tener, and Micruroides euryxanthus, as well as numerous Micrurus species distributed throughout Central and South America. Venom exerts predominantly neurotoxic effects through presynaptic and postsynaptic neuromuscular blockade, leading to progressive weakness, cranial nerve involvement, and descending paralysis that may culminate in respiratory failure. Early manifestations include ptosis, dysarthria, dysphagia, and bulbar dysfunction, often in the absence of significant local swelling or pain.

This educational activity enhances clinician competence in the timely recognition, evaluation, and management of coral snake envenomation. Participants gain practical insight into venom pathophysiology, species identification, and regional epidemiology, as well as evidence-based strategies for airway management, respiratory monitoring, and appropriate antivenom administration. Emphasis is placed on distinguishing elapid envenomation from pit viper bites and recognizing early neuromuscular compromise. Collaboration among emergency clinicians, toxicologists, nurses, respiratory therapists, and poison control specialists is highlighted as a critical factor in optimizing outcomes, facilitating rapid intervention, minimizing complications, and improving survival through coordinated, patient-centered care.

Objectives:

• Identify the clinical and diagnostic features indicative of coral snake envenomation.
• Determine best practices for managing coral snake envenomation through timely airway protection, appropriate use of antivenom, and coordinated supportive care.
• Improve patient awareness about identifying coral snake bites, limiting venom spread, and seeking immediate professional care.
• Implement interprofessional team strategies to enhance care coordination and communication in coral snake envenomation, ultimately improving outcomes.

Introduction

Coral snakes belong to the elapid family (Elapidae), which also includes cobras, kraits, and mambas. Old World elapids, distributed across Africa, Asia, and Australia, exhibit variable combinations of neurotoxic and cytotoxic venom effects. In contrast, New World elapids, specifically coral snakes of the genera Micrurus and Micruroides, are predominantly neurotoxic, producing minimal local injury and delayed respiratory paralysis.[1] Medically significant North American species include the Eastern coral snake (Micrurus fulvius), found in the southeastern United States (US); the Texas coral snake (Micrurus tener), found in Texas and northeastern Mexico; and the Arizona or Sonoran coral snake (Micruroides euryxanthus), found in the desert southwestern United States. However, the Sonoran coral snake does not produce envenomation requiring medical intervention.[2]

These small, slender serpents typically measure 40 to 70 cm in length and possess smooth scales with characteristic red, yellow, and black banding, a warning pattern frequently mimicked by nonvenomous species (see Image. Coral Snake). Coral snakes have short, fixed anterior fangs (proteroglyphous dentition) that deliver venom through a chewing mechanism requiring prolonged contact. The venom contains potent α- and β-neurotoxins that impair neuromuscular transmission at both presynaptic and postsynaptic sites.[3][4]

Coral snakes are generally reclusive and nonaggressive, occupying woodland, sandy, or brush-covered areas across the southeastern and southwestern US. Envenomation typically results from handling or accidental contact.[5] Venom is absorbed via lymphatic and vascular pathways, producing systemic neurotoxicity with minimal local effects. Initial symptoms often include paresthesias and mild weakness, followed by cranial nerve involvement and descending flaccid paralysis. The most serious complication is respiratory failure, necessitating prompt airway management and antivenin administration.[6] Symptoms may be delayed up to 12 to 13 hours, but can progress rapidly to respiratory failure and death if untreated.

Etiology

Envenomation by M fulvius and M tener typically produces minimal local effects but can result in significant neurotoxicity, including cranial neuropathies, bulbar weakness, and potentially fatal delayed respiratory paralysis. In contrast, M euryxanthus envenomation is not known to cause clinically significant symptoms in humans.[7] Although M euryxanthus venom is highly neurotoxic in animal models, dominated by potent α-neurotoxins (3-finger toxins, 3FTx) lethal to mice, no well-documented cases of severe or life-threatening human envenomation have been described.[8] The absence of significant human toxicity from M euryxanthus may reflect differences in venom composition, lower venom yield, or limited human exposure.[9]

Epidemiology

North American coral snake envenomation is rare, accounting for less than 2% of all venomous snakebites in the US. Most cases occur in the Southeast (primarily Florida) and Southwest (Texas, New Mexico, Arizona). Most patients are male (approximately 77%) and adults older than 20 (70%), although children younger than 10 years account for approximately 12% of cases.[10] Intentional handling is a common risk factor, and many exposures occur during recreational or occupational activities. Hospital admission rates for coral snakebites are similar to those for pit viper bites, with severe outcomes more frequent in children younger than 6 years. Fatalities are extremely rare.[11][12]

Nationally, approximately 8000 to 10,000 snakebite cases are treated annually in the US; coral snakebites typically account for fewer than 100 cases per year.[13] Worldwide, the incidence of coral snake envenomation is higher in Central and South America but remains substantially lower than that of pit viper bites. The total annual incidence of all snakebites in the Americas is approximately 57,500, with coral snakes representing a minority of cases. Most incidents occur in regions where coral snakes are native, and intentional contact is a primary risk factor.[14]

Pathophysiology

North American coral snakes produce both α- and β-neurotoxins in their venom, with relative amounts varying by species and geographic region. α-Neurotoxins are typically 3-finger toxins that act as competitive antagonists, binding postsynaptically to nicotinic acetylcholine receptors and causing reversible nondepolarizing neuromuscular blockade.[15] β-Neurotoxins are primarily phospholipase A2 enzymes that act presynaptically, disrupting acetylcholine release and causing irreversible destruction of motor nerve terminals via membrane phospholipid hydrolysis.[16][17]

Variability in venom composition is clinically significant because both toxin types contribute to the progressive descending paralysis observed in envenomation. Presynaptic β-neurotoxins are less susceptible to antivenin neutralization once internalized. Sanchez et al reported that the median lethal dose (LD50) of M fulvius venom (mean LD50 0.279 mg/kg) is significantly lower than that of M tener venom (mean LD50 0.779 mg/kg). This difference in toxicity corresponds to the more severe clinical effects observed following Eastern coral snake envenomations.[18]

History and Physical

Coral snake envenomation varies according to snake species, venom amount and potency, bite location, and patient comorbidities. Accurate identification of the snake species is essential for administering the appropriate antivenom. Coral snake fangs are small and inflexible, making envenomation less likely. Approximately 40% of individuals bitten do not experience venom effects.[19] Bites often do not produce easily identifiable puncture wounds, and local symptoms are typically mild.

Neurological symptoms usually manifest several hours after the bite, with complications reported up to 13 hours postexposure. Local effects may include numbness, paresthesia, and pain at the bite site. Classic neurological findings include bulbar deficits such as ptosis, diplopia, dysphagia, stridor, muscle weakness, fasciculations, and paralysis. Respiratory failure from descending neuromuscular weakness is the primary cause of death in severe envenomation cases.[20]

Evaluation

Evaluation of individuals who experience coral snake envenomation should focus on neurologic deficits and respiratory compromise.[21] Serial pulmonary function testing aids in predicting respiratory insufficiency. Rhabdomyolysis may occur in M fulvius envenomation and should be assessed as clinically indicated, with patients exhibiting elevated creatine phosphokinase levels. Unlike pit viper envenomation, significant tissue necrosis at the bite site and coagulopathies are uncommon in coral snake bites. Consequently, dramatic changes in skin appearance are often absent.

Treatment / Management

Prehospital management of coral snakebites focuses on scene safety, removal from the site of envenomation, and minimizing systemic venom absorption through immobilization and supportive care. The affected extremity should be immobilized in a neutral position relative to the heart using a loose splint to reduce venom lymphatic circulation. Any jewelry or restrictive items should be removed, as swelling may develop at the bite site. Tourniquets and venom extraction methods—including incision, oral suction, or mechanical devices—as well as cryotherapy, are not recommended.

The American Heart Association and the American Red Cross recommend applying a pressure-immobilization bandage (PIB) along the entire length of the bitten extremity, provided this step does not delay transport to the hospital.[22] A PIB with 40- to 70-mm Hg pressure in the upper extremity and 55- to 70-mm Hg in the lower extremity can reduce lymphatic flow, potentially decreasing systemic venom absorption. Proper placement may be challenging for first responders, and incorrect application could increase the risk of permanent limb injury. PIB may be considered when the responder is adequately trained, local effects are minimal, and rapid neurotoxicity is a concern.

Hospital management of coral snake envenomation involves early administration of antivenin and supportive care. Consultation with an in-house medical toxicology service or regional poison control center is recommended. Restrictive clothing should be removed if not already done, and the bite site should be cleaned and inspected for retained foreign bodies, including fangs or teeth. Patients with suspected coral snakebites should be observed in an intensive care unit for at least 24 hours due to the risk of delayed neurotoxicity and respiratory failure. The onset of neurotoxicity can be rapid, so endotracheal intubation is indicated at the first sign of any bulbar deficits. Consensus guidelines and expert opinions dominate in the absence of high-quality studies, sometimes offering conflicting recommendations.[23][24]

The North American Coral Snake Antivenin (NACSA) is a horse-derived immunoglobulin (whole immunoglobulin G) approved by the US Food and Drug Administration for the treatment of envenomations from the Eastern (M fulvius) and Texas (M tener) coral snakes in adults and children. NACSA is produced by immunizing healthy horses with M fulvius venom. Indications for administration include the development of any neurologic abnormalities. 

Historically, Wyeth-produced NACSA was recommended for all patients with confirmed or strongly suspected coral snake envenomation, as neuromuscular toxicity can develop rapidly, and symptoms may not reverse following antivenom treatment. However, results from a study comparing patients who received empiric antivenin with those treated after symptom onset found that a conservative approach did not lead to worse outcomes.[25][26] Empiric treatment of asymptomatic individuals was associated with higher rates of moderate-to-severe adverse events. Expert consensus now recommends against administering NACSA empirically before symptom development.

NACSA is currently available from Pfizer, and administration to asymptomatic individuals is contraindicated on the package insert. In adults and adolescents, the dose may range from 3 to 5 vials, depending on treatment response. If NACSA administration is delayed, a trial of an acetylcholinesterase inhibitor, such as neostigmine, may be reasonable to reverse neuromuscular weakness.[27][28]

The main adverse effects of NACSA are immediate and delayed hypersensitivity reactions.[29] Immediate hypersensitivity reactions can occur within minutes to hours after administration and include urticaria, bronchospasm, hypotension, and angioedema. In a large case series, approximately 18% of patients receiving NACSA experienced adverse reactions, with allergic-type responses the most common. These reactions primarily result from the animal-derived immunoglobulins in the antivenin. Managing allergic reactions is similar to that of other allergic reactions and may include antihistamines, corticosteroids, and epinephrine, as indicated.

Serum sickness is a well-documented delayed complication and correlates directly with the amount of antivenin administered. Onset typically occurs 5 to 14 days postadministration and manifests as fever, rash, urticaria, pruritus, lymphadenopathy, arthralgias, and malaise. Treatment includes corticosteroids (prednisone 2 mg/kg; maximum adult dose 60 mg/day), divided into 2 daily doses and tapered over 2 to 3 weeks. Oral antihistamines may also be used for symptomatic relief.

Differential Diagnosis

The differential diagnosis of coral snake envenomation includes hymenoptera stings, ciguatera toxicity, neurotoxic and paralytic shellfish poisoning, scorpion envenomation, and crotaline (pit viper) envenomation. The timing of symptom development, characteristic neurotoxic signs, and exclusion of alternative causes of paralysis guide early recognition.

Prognosis

Coral snake envenomation generally has a favorable outlook when appropriate medical treatment is available, with death being extremely uncommon in modern healthcare environments. US poison control surveillance data from 1983 to 2007 reported no fatalities attributable to coral snake envenomation. Only 2 deaths were recorded in a comprehensive Brazilian review of 150 coral snake envenomation cases from 1867 to 2014, both in 1933, involving individuals who developed paralysis and respiratory failure without access to mechanical ventilation. Favorable outcomes depend on early recognition and close monitoring, as symptom onset may be delayed up to 12 to 13 hours after the bite. During this latent period, clinical appearance may remain deceptively benign before the onset of potentially life-threatening neurotoxicity.

Most cases resolve with complete recovery, although the clinical course varies considerably. The hallmark of systemic envenomation is neuromuscular blockade, manifesting as ptosis, weakness, dysphagia, and potential progression to descending paralysis and respiratory failure. Serious complications, such as respiratory failure requiring mechanical ventilation, can occur but remain relatively uncommon.

A pediatric case series described prolonged hospitalization complicated by respiratory failure, bulbar palsy, and ataxia, yet all cases survived to discharge. With appropriate intensive care monitoring and ventilatory support, full recovery is expected in most cases. Once established, neurotoxic effects may necessitate prolonged respiratory support, as presynaptic neurotoxins are not readily reversible even with antivenom, but permanent sequelae are uncommon when timely supportive care is provided.

Complications

The primary complication of coral snake envenomation is progressive neuromuscular paralysis, which can lead to respiratory failure requiring mechanical ventilation. This neurotoxicity manifests as a descending, flaccid paralysis that begins with cranial nerve involvement, including ptosis, dysarthria, dysphagia, and blurred vision, and may progress to complete respiratory paralysis. Onset of neurotoxic effects may be delayed up to 12 to 13 hours after the bite, rendering early asymptomatic presentation misleading. Presynaptic neurotoxins are of particular concern because, once internalized within nerve terminals, reversibility is limited even with antivenom, often necessitating prolonged respiratory support. Additional neurologic manifestations include altered mental status, tremors, hypersalivation, generalized weakness, and gait impairment.

Less common but documented complications include mild myotoxicity, nephrotoxicity, and transient sensory disturbances. Elevated creatine kinase levels, reflecting mild systemic myotoxicity, have been reported in several cases, including envenomation by M hemprichii.[30] Nephrotoxicity may occur through direct venom-mediated injury involving inflammatory cytokines, oxidative stress, and reduced renal perfusion, although this finding is more frequently associated with Central and South American coral snake species.

A rare complication described in 2 patients was transient ageusia lasting approximately 3 to 4 weeks following envenomation.[31] In contrast to pit viper envenomation, coral snake bites typically do not produce significant local tissue necrosis, coagulopathy, or hemorrhagic complications. Delayed treatment-related complications include serum sickness following antivenom administration.

Deterrence and Patient Education

The primary strategy for preventing coral snake envenomation is avoidance of snake contact through protective measures and environmental awareness. Using heavy, ankle-high or taller boots, along with long sleeves and pants, is recommended in snake-inhabited areas, particularly during warm weather months when snake activity increases. Most bites occur when individuals startle, step on, or handle snakes. Careful inspection of areas where hands or feet are placed reduces this risk.

Following a bite, immediate medical evaluation is required even in the absence of symptoms, as clinical manifestations may be delayed up to 12 to 13 hours. Movement to a safe area, activation of emergency medical services, removal of constricting jewelry near the bite site before swelling develops, and cleansing of the area with soap and water, when available, are appropriate initial measures.[32]

Attempts to capture or handle the snake, even if dead, as well as application of tourniquets, pressure bandages, wound incision, suction, ice, topical agents, or herbal remedies, should be avoided. Self-transport to the hospital is discouraged, as envenomation may precipitate syncope. The potential for delayed, life-threatening neurotoxicity, including respiratory compromise, muscle weakness, and paralysis, necessitates prompt evaluation regardless of initial clinical appearance.

Pearls and Other Issues

Essential considerations in the management of coral snake envenomation include the following:

• Coral snake envenomation is rare in North America but may produce delayed neurotoxicity, with symptoms developing up to 12 to 13 hours postbite.
• Local manifestations are minimal. Cranial nerve deficits and progressive muscle weakness can result in respiratory failure, the primary cause of mortality.
• α- and β-neurotoxins disrupt neuromuscular transmission via postsynaptic blockade and presynaptic inhibition of acetylcholine release.
• Definitive treatment consists of Pfizer's NACSA, a horse-derived immunoglobulin G antibody.
• Timely airway management and antivenin administration generally result in full recovery. Delayed intervention increases the risk of respiratory failure and death.

Unlike pit viper or scorpion envenomation, coral snake bites rarely produce significant local injury, with delayed cranial nerve and muscular symptoms predominating. Education should emphasize early recognition and prompt hospital care to prevent respiratory compromise.

Enhancing Healthcare Team Outcomes

Coral snake envenomation is a rare but potentially fatal neurotoxic emergency requiring early recognition, airway management, and prompt antivenin administration. Initial local signs are often subtle. Thus, clinicians must maintain a high index of suspicion in patients with a credible snakebite history and emerging neurological deficits such as ptosis, dysarthria, or respiratory weakness. Early airway intervention and rapid transport are critical to preventing respiratory failure and improving outcomes.

Prehospital providers play a pivotal role in early management and communication. Emergency medical services personnel should ensure scene safety, immobilize the affected limb, avoid incision or suction, and provide rapid transport while notifying the receiving facility of suspected envenomation. Effective communication between emergency medical services and the emergency department facilitates immediate preparation of airway equipment, access to antivenin, and consultation with poison control.

Within the hospital, an interprofessional team, including emergency clinicians, medical toxicologists, intensivists, advanced practitioners, nurses, pharmacists, respiratory therapists, and poison control specialists, collaborates to provide coordinated, patient-centered care. Medical toxicologists provide guidance on antivenin indications, dosing, and monitoring for adverse reactions, as well as recommendations for supportive care and disposition. Clinicians lead airway assessments and determine treatment strategies, while nurses monitor patients for early neurologic and respiratory compromise. Pharmacists oversee the safe preparation and administration of antivenin, and respiratory therapists provide ventilatory support. Ethical and clear communication is fundamental at every stage, ensuring informed consent, reducing errors, and promoting patient safety. Continued education, simulation training, and post-case reviews support team performance and improve outcomes in coral snake envenomation.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med. 2002 Aug 01;347(5):347-56. [PubMed: 12151473]

2.

Seifert SA, Armitage JO, Sanchez EE. Snake Envenomation. N Engl J Med. 2022 Jan 06;386(1):68-78. [PMC free article: PMC9854269] [PubMed: 34986287]

3.

McAninch SA, Morrissey RP, Rosen P, Meyer TA, Hessel MM, Vohra MH. Snake Eyes: Coral Snake Neurotoxicity Associated With Ocular Absorption of Venom and Successful Treatment With Exotic Antivenom. J Emerg Med. 2019 May;56(5):519-522. [PubMed: 30879857]

4.

Sasaki J, Khalil PA, Chegondi M, Raszynski A, Meyer KG, Totapally BR. Coral snake bites and envenomation in children: a case series. Pediatr Emerg Care. 2014 Apr;30(4):262-5. [PubMed: 24694882]

5.

Velagapudi ME, Navarro JJ, Hill AE, Darracq MA, Thornton SL. Epidemiology and characteristics of coral snake bites reported to the National Poison Data System (2006‒2022). J Am Coll Emerg Physicians Open. 2024 Oct;5(5):e13296. [PMC free article: PMC11449674] [PubMed: 39371963]

6.

Hewett Brumberg EK, Douma MJ, Alibertis K, Charlton NP, Goldman MP, Harper-Kirksey K, Hawkins SC, Hoover AV, Kule A, Leichtle S, McClure SF, Wang GS, Whelchel M, White L, Lavonas EJ., American Heart Association and American Red Cross. 2024 American Heart Association and American Red Cross Guidelines for First Aid. Circulation. 2024 Dec 10;150(24):e519-e579. [PubMed: 39540278]

7.

Mohanty CR, Radhakrishnan RV, Barik AK, Samuel SP, Kumar AR. Comment on Regional Differences in Systemic Toxicity Following Texas Coral Snake (Micrurus tener) Envenomations by Greene et al. Wilderness Environ Med. 2025 Dec;36(4):589-590. [PubMed: 40501352]

8.

Bénard-Valle M, Neri-Castro E, Elizalde-Morales N, Olvera-Rodríguez A, Strickland J, Acosta G, Alagón A. Protein composition and biochemical characterization of venom from Sonoran Coral Snakes (Micruroides euryxanthus). Biochimie. 2021 Mar;182:206-216. [PubMed: 33485932]

9.

Walter FG, Stolz U, Shirazi F, McNally J. Temporal analyses of coral snakebite severity published in the American Association of Poison Control Centers' Annual Reports from 1983 through 2007. Clin Toxicol (Phila). 2010 Jan;48(1):72-8. [PubMed: 20070180]

10.

Langley R, Haskell MG, Hareza D, King K. Fatal and Nonfatal Snakebite Injuries Reported in the United States. South Med J. 2020 Oct;113(10):514-519. [PubMed: 33005969]

11.

Seifert SA, Boyer LV, Benson BE, Rogers JJ. AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005. Clin Toxicol (Phila). 2009 Apr;47(4):327-35. [PubMed: 19514880]

12.

Greene SC, Folt J, Wyatt K, Brandehoff NP. Epidemiology of fatal snakebites in the United States 1989-2018. Am J Emerg Med. 2021 Jul;45:309-316. [PubMed: 33046301]

13.

Wood A, Schauben J, Thundiyil J, Kunisaki T, Sollee D, Lewis-Younger C, Bernstein J, Weisman R. Review of Eastern coral snake (Micrurus fulvius fulvius) exposures managed by the Florida Poison Information Center Network: 1998-2010. Clin Toxicol (Phila). 2013 Sep-Oct;51(8):783-8. [PubMed: 23962099]

14.

Chippaux JP. Incidence and mortality due to snakebite in the Americas. PLoS Negl Trop Dis. 2017 Jun;11(6):e0005662. [PMC free article: PMC5495519] [PubMed: 28636631]

15.

Greene S, Ruha AM, Campleman S, Brent J, Wax P., ToxIC Snakebite Study Group. Epidemiology, Clinical Features, and Management of Texas Coral Snake (Micrurus tener) Envenomations Reported to the North American Snakebite Registry. J Med Toxicol. 2021 Jan;17(1):51-56. [PMC free article: PMC7785759] [PubMed: 32803694]

16.

Francis BR, da Silva Júnior NJ, Seebart C, Casais e Silva LL, Schmidt JJ, Kaiser II. Toxins isolated from the venom of the Brazilian coral snake (Micrurus frontalis frontalis) include hemorrhagic type phospholipases A2 and postsynaptic neurotoxins. Toxicon. 1997 Aug;35(8):1193-203. [PubMed: 9278969]

17.

Silva A, Cristofori-Armstrong B, Rash LD, Hodgson WC, Isbister GK. Defining the role of post-synaptic α-neurotoxins in paralysis due to snake envenoming in humans. Cell Mol Life Sci. 2018 Dec;75(23):4465-4478. [PMC free article: PMC11105319] [PubMed: 30069700]

18.

Sánchez EE, Lopez-Johnston JC, Rodríguez-Acosta A, Pérez JC. Neutralization of two North American coral snake venoms with United States and Mexican antivenoms. Toxicon. 2008 Feb;51(2):297-303. [PMC free article: PMC3293456] [PubMed: 18054059]

19.

Kitchens CS, Van Mierop LH. Envenomation by the Eastern coral snake (Micrurus fulvius fulvius). A study of 39 victims. JAMA. 1987 Sep 25;258(12):1615-8. [PubMed: 3625968]

20.

Bucaretchi F, Capitani EM, Vieira RJ, Rodrigues CK, Zannin M, Da Silva NJ, Casais-e-Silva LL, Hyslop S. Coral snake bites (Micrurus spp.) in Brazil: a review of literature reports. Clin Toxicol (Phila). 2016 Mar;54(3):222-34. [PubMed: 26808120]

21.

Strauch MA, Souza GJ, Pereira JN, Ramos TDS, Cesar MO, Tomaz MA, Monteiro-Machado M, Patrão-Neto FC, Melo PA. True or false coral snake: is it worth the risk? A Micrurus corallinus case report. J Venom Anim Toxins Incl Trop Dis. 2018;24:10. [PMC free article: PMC5894131] [PubMed: 29651298]

22.

Markenson D, Ferguson JD, Chameides L, Cassan P, Chung KL, Epstein J, Gonzales L, Herrington RA, Pellegrino JL, Ratcliff N, Singer A. Part 17: first aid: 2010 American Heart Association and American Red Cross Guidelines for First Aid. Circulation. 2010 Nov 02;122(18 Suppl 3):S934-46. [PubMed: 20956233]

23.

Bhaumik S, Beri D, Lassi ZS, Jagnoor J. Interventions for the management of snakebite envenoming: An overview of systematic reviews. PLoS Negl Trop Dis. 2020 Oct;14(10):e0008727. [PMC free article: PMC7584233] [PubMed: 33048936]

24.

Turner D, Winter S, Winkel K, MacIsaac C, Padula A, Braitberg G. Review article: Let us talk about snakebite management: A discussion on many levels. Emerg Med Australas. 2019 Aug;31(4):542-545. [PubMed: 31207174]

25.

Silva A, Hodgson WC, Isbister GK. Antivenom for Neuromuscular Paralysis Resulting From Snake Envenoming. Toxins (Basel). 2017 Apr 19;9(4) [PMC free article: PMC5408217] [PubMed: 28422078]

26.

Bickler PE, Abouyannis M, Bhalla A, Lewin MR. Neuromuscular Weakness and Paralysis Produced by Snakebite Envenoming: Mechanisms and Proposed Standards for Clinical Assessment. Toxins (Basel). 2023 Jan 06;15(1) [PMC free article: PMC9861841] [PubMed: 36668869]

27.

Bucaretchi F, Hyslop S, Vieira RJ, Toledo AS, Madureira PR, de Capitani EM. Bites by coral snakes (Micrurus spp.) in Campinas, State of São Paulo, Southeastern Brazil. Rev Inst Med Trop Sao Paulo. 2006 May-Jun;48(3):141-5. [PubMed: 16847503]

28.

Vital Brazil O, Vieira RJ. Neostigmine in the treatment of snake accidents caused by Micrurus frontalis: report of two cases (1). Rev Inst Med Trop Sao Paulo. 1996 Jan-Feb;38(1):61-7. [PubMed: 8762642]

29.

de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharmacol. 2016 Mar;81(3):446-52. [PMC free article: PMC4767202] [PubMed: 26256124]

30.

Bisneto PF, Araújo BDS, Pereira HDS, Mendonça da Silva I, Sachett JAG, Bernarde PS, Monteiro WM, Kaefer IL. Envenomations by coral snakes in an Amazonian metropolis: Ecological, epidemiological and clinical aspects. Toxicon. 2020 Oct 15;185:193-202. [PubMed: 32710896]

31.

Bucaretchi F, Borrasca-Fernandes CF, De Capitani EM, Hyslop S. Consecutive envenomation of two men bitten by the same coral snake (Micrurus corallinus). Clin Toxicol (Phila). 2020 Feb;58(2):132-135. [PubMed: 31079507]

32.

Lieu K, Livshits Z, LeSaint KT. Venomous Snakes and Snakebites. JAMA. 2025 Oct 28;334(16):1494. [PubMed: 40875216]

Disclosure: Dallas Beaird declares no relevant financial relationships with ineligible companies.

Disclosure: Vincent Lee declares no relevant financial relationships with ineligible companies.